Optical

Thought Leadership & Innovation Foundation Announces Strategic Partnership with American Macular Degeneration Foundation, Debuts Patient Testimonial Video Featuring TLI Fellow

Retrieved on: 
Monday, February 5, 2024

Thought Leadership & Innovation Foundation (TLI) , a not-for-profit organization that works at the nexus of science, technology and public health, today announces a strategic partnership with the American Macular Degeneration Foundation (AMDF), beginning with the debut of a patient testimonial video produced by the AMDF and featuring TLI Fellow, Laura Carabello, who documents her timely intervention and management of macular degeneration.

Key Points: 
  • Thought Leadership & Innovation Foundation (TLI) , a not-for-profit organization that works at the nexus of science, technology and public health, today announces a strategic partnership with the American Macular Degeneration Foundation (AMDF), beginning with the debut of a patient testimonial video produced by the AMDF and featuring TLI Fellow, Laura Carabello, who documents her timely intervention and management of macular degeneration.
  • As a patient advocate for AMDF and as Chair of the TLI Fellows, Carabello urges people to understand their risk for macular degeneration, recognize symptoms, seek early treatment and be compliant with ongoing therapy.
  • “Laura's journey provides an insightful and assuring perspective, chronicling her personal challenges with macular degeneration from diagnosis to clinical intervention.
  • Together, TLI and AMDF are dedicated to advancing awareness, research and support, forging a path towards a future where the impact of macular degeneration is minimized, and the gift of sight is preserved.

Omeros Corporation Announces Additional Royalty Monetization with DRI Healthcare Trust

Retrieved on: 
Thursday, February 1, 2024

Omeros Corporation (Nasdaq: OMER) today announced the sale to DRI Healthcare Acquisitions LP (“DRI”), a wholly owned subsidiary of DRI Healthcare Trust, of an expanded interest in certain royalty payments based on net sales of OMIDRIA in the United States.

Key Points: 
  • Omeros Corporation (Nasdaq: OMER) today announced the sale to DRI Healthcare Acquisitions LP (“DRI”), a wholly owned subsidiary of DRI Healthcare Trust, of an expanded interest in certain royalty payments based on net sales of OMIDRIA in the United States.
  • Under the terms of that asset purchase agreement, Omeros is entitled to receive royalties on net sales of OMIDRIA.
  • Today Omeros and DRI expanded their royalty purchase agreement, resulting in Omeros receiving from DRI an upfront payment of $115 million and entitling DRI to receive the remainder of Omeros’ royalties on U.S. net sales of OMIDRIA payable between January 1, 2024 and December 31, 2031.
  • “We are pleased to have partnered again with DRI, further monetizing our OMIDRIA royalty stream,” said Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros.

Aviceda Therapeutics Announces First Patient Dosed in Part 2 of the Phase 2/3 SIGLEC Clinical Trial Assessing AVD-104 for the Treatment of Geographic Atrophy

Retrieved on: 
Thursday, February 1, 2024

“In Part 1 of SIGLEC, we found that AVD-104 had a positive safety profile, and that patients with GA dosed with AVD-104 showed BCVA improvements at 3 months (Found HERE ).

Key Points: 
  • “In Part 1 of SIGLEC, we found that AVD-104 had a positive safety profile, and that patients with GA dosed with AVD-104 showed BCVA improvements at 3 months (Found HERE ).
  • Patients will be dosed for 12 months, with the opportunity to remain in the study for an additional 12 months.
  • Those assigned to treatment with AVD-104 will receive either low-dose AVD-104, high-dose AVD-104, or the active comparator.
  • Numerous other visual functional and anatomic efficacy measures will also be explored and compared between AVD-104 and the active comparator.

Eye Health America Announces Newest Acquisition of Loris Eye Associates

Retrieved on: 
Thursday, February 1, 2024

Welcome Dr. Tracy Ray and Loris team to our exceptional roster of eye care professionals.

Key Points: 
  • Welcome Dr. Tracy Ray and Loris team to our exceptional roster of eye care professionals.
  • Founded in 2018 by LLR Partners, Clemson Eye, and The Eye Associates, EHA is led by experienced eye care leadership, providing superior support to partner practices.
  • Eye Health America (EHA) is a leading eyecare provider focused on partnering with culturally aligned ophthalmology practices, optometry practices and ambulatory surgery centers across the Southeast U.S. to provide superior strategic, financial, and operational support for best-in-class eye care.
  • Member practices include Clemson Eye, Piedmont Surgery Center, EHA Surgery Center Seneca, The Surgery & Laser Center, Carolinas Centers for Sight, Florence Surgery and Laser Center, Southeast Retina Center, Augusta Retina Laser Surgicare, The Eye Associates, The Eye Associates Surgery Center, EHA Surgery Center Sarasota, Eye Centers of Florida, Surgicare Center, Updegraff Laser Vision, Tampa Bay Eye Surgery Center, West Georgia Eye Care Center, Eye Surgery Center of West Georgia, and many other top eyecare providers.

Guide Dogs for the Blind Partners With American Printing House for the Blind on Summer Careers and Canine Program for Young Adults

Retrieved on: 
Wednesday, January 31, 2024

Guide Dogs for the Blind (GDB) and American Printing House for the Blind (APH) ConnectCenter have extended a partnership to offer a career program for young people who are blind or have low vision through Careers & Canine Connections, a weeklong immersive program for young adults aged 18-24.

Key Points: 
  • Guide Dogs for the Blind (GDB) and American Printing House for the Blind (APH) ConnectCenter have extended a partnership to offer a career program for young people who are blind or have low vision through Careers & Canine Connections, a weeklong immersive program for young adults aged 18-24.
  • View the full release here: https://www.businesswire.com/news/home/20240131410116/en/
    A young woman with long dark hair smiles while sitting with a yellow Labrador Retriever from Guide Dogs for the Blind.
  • Although it is not a guide dog training program, Careers & Canine Connections is tailored for young job seekers interested in exploring the guide dog lifestyle.
  • To learn more, visit Guide Dogs for the Blind’s website or attend the APH's information session on February 8th.

Glaukos to Release Fourth Quarter and Full Year 2023 Financial Results after Market Close on February 21

Retrieved on: 
Wednesday, January 31, 2024

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release fourth quarter and full year 2023 financial results after the market close on Wednesday, February 21, 2024.

Key Points: 
  • Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release fourth quarter and full year 2023 financial results after the market close on Wednesday, February 21, 2024.
  • The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m.
  • A link to the live webcast will be available on the company’s website at http://investors.glaukos.com .
  • To participate in the conference call, please dial 888-210-2212 (U.S.) or 646-960-0390 (International) and enter Conference ID 7935742.

TRAQC, ClearVision, and UriMetrics Awarded Top Three Places at 2024 SPIE Startup Challenge

Retrieved on: 
Wednesday, January 31, 2024

Yesterday, at a ceremony during SPIE Photonics West , TRAQC was announced the winner of the $10,000 top prize at the 14th annual SPIE Startup Challenge .

Key Points: 
  • Yesterday, at a ceremony during SPIE Photonics West , TRAQC was announced the winner of the $10,000 top prize at the 14th annual SPIE Startup Challenge .
  • Their real-time inspection solution for the printed electronics industry utilizes THz radiation and metamaterial technology to ensure quality while reducing waste.
  • View the full release here: https://www.businesswire.com/news/home/20240131233858/en/
    Jenoptik’s Ralf Kuschnereit, TRAQC's Benjamin Dringoli, and 2024 SPIE President Jennifer Barton.
  • All cash prizes are provided by SPIE Startup Challenge Founding Partner Jenoptik.

Located in Seoul, Korea, Topcon Korea Medical Co., Ltd. (TKM) Was Established and Formally Launched in 2023.

Retrieved on: 
Friday, February 2, 2024

Topcon Corporation (HQ: Itabashi-ku, Tokyo; President: Takashi Eto) (henceforth Topcon Healthcare) has established Topcon Korea Medical Co., Ltd. (HQ: Seoul, South Korea, President: Artur Chu) (henceforth TKM) to strengthen and expand its eyecare business in South Korea.

Key Points: 
  • Topcon Corporation (HQ: Itabashi-ku, Tokyo; President: Takashi Eto) (henceforth Topcon Healthcare) has established Topcon Korea Medical Co., Ltd. (HQ: Seoul, South Korea, President: Artur Chu) (henceforth TKM) to strengthen and expand its eyecare business in South Korea.
  • In South Korea, as in other developed countries, the government is responding to the increase in eye disease associated with an aging population.
  • "Introducing Topcon Korea Medical Co., Ltd., empowering excellence in the Korean market.
  • With a firm foundation built on understanding the needs of our customers in Korea, TKM is poised to revolutionize the industry landscape.

NovaBay Pharmaceuticals Reports 64% Year-Over-Year Growth in Avenova Unit Subscription-Based Sales

Retrieved on: 
Tuesday, January 30, 2024

NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces a 64% increase in online subscription-based unit sales for its Avenova® Lid & Lash Spray Solution and a 38% increase in subscription-based customers in 2023 over the prior year on Amazon.com and Avenova.com.

Key Points: 
  • NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces a 64% increase in online subscription-based unit sales for its Avenova® Lid & Lash Spray Solution and a 38% increase in subscription-based customers in 2023 over the prior year on Amazon.com and Avenova.com.
  • A substantial 24% of all online sales were from subscribers in 2023, up from approximately 14% in 2022.
  • In addition, of the more than 13,000 customer reviews across all online channels, Avenova Spray averaged a 4.5-star overall rating.
  • “Generating sales through the subscriber base provides efficient and consistent revenue, allowing us to better manage our sales and marketing spend.

New Long-Term Data for Genentech’s Vabysmo Show Sustained Retinal Drying and Vision Improvements in Retinal Vein Occlusion (RVO)

Retrieved on: 
Thursday, February 1, 2024

In addition, patients in the studies maintained vision gains and robust retinal drying achieved in the first 24 weeks of the studies for more than one year.

Key Points: 
  • In addition, patients in the studies maintained vision gains and robust retinal drying achieved in the first 24 weeks of the studies for more than one year.
  • Retinal drying is an important clinical measure as swelling from excess fluid in the back of the eye has been associated with distorted and blurred vision.
  • In both studies, Vabysmo was well tolerated and the safety profile was consistent with previous studies.
  • “The sustained vision improvements and retinal drying seen up to 72 weeks reaffirm Vabysmo as an effective treatment for retinal vein occlusion,” said Ramin Tadayoni, M.D., Ph.D., head of ophthalmology at Université Paris Cité in Paris and president of EURETINA, who is presenting the data at Angiogenesis.